Jennifer Curtis

Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial

Panagiotis A. Konstantinopoulos, William T. Barry, Michael J. Birrer et al. · The Lancet Oncology · 2019 · 262 citations

Medicine, Oncology, Pharmacology +13

Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

Panagiotis A. Konstantinopoulos, Su-Chun Cheng, Andrea E. Wahner Hendrickson et al. · The Lancet Oncology · 2020 · 232 citations · Full text

Medicine, Gynecology, Oncology +13

Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer

Joyce F. Liu, Christina I. Herold, Kathryn P. Gray et al. · JAMA Oncology · 2019 · 227 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer

Panagiotis A. Konstantinopoulos, Weixiu Luo, Joyce F. Liu et al. · Journal of Clinical Oncology · 2019 · 218 citations · Full text

Medicine, Immunology, Oncology +17

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer

J.F. Liu, William T. Barry, Michael J. Birrer et al. · Annals of Oncology · 2019 · 189 citations · Full text

Medicine, Oncology, Pharmacotherapy +16